AI-Powered Biopharma Intelligence — a business, product, and growth diagnostic built entirely from the live site and its real competitive set.
Subject
doloxe.com
Sector
Biopharma Market & Competitive Intelligence — Vertical Data SaaS
Prepared
23 June 2026
Engagement team
Strategy · Product · UX/CRO · SEO · Growth · Sales · Finance · AI
Pages reviewed
11 live pages + independent competitor & market research
Every finding below traces back to the live doloxe.com site — homepage, About Us, all six Key Feature pages, Report Store, Daily News, Contact Us and Sign-Up — plus independent research into the named competitive set (IQVIA, Clarivate Cortellis, Evaluate, GlobalData Pharmaceuticals, DealForma, AlphaSense) and category market sizing. Nothing below is generic template advice; where a number is modeled rather than observed, it is labeled as such.
Reading note — every score in this deck is a directional judgment by the engagement team, not a certified metric. Financial figures in Phase 11 are explicitly modeled from comparable vertical-SaaS benchmarks, not Doloxe's actual books.
Doloxe sells access to a centralized biopharma data repository across six modules: GenAI-powered drug/company/trial search, a 12,000+ manufacturer supply-chain map (BioPharma KSM), a deal-and-pipeline tracker (360 BioPharma Tracker), a clinical-trial protocol optimizer (Clinical Trials Accelerators), an AI drug-repurposing recommender, and a pricing/HTA/reimbursement engine (HEOR Tracker) — plus a separate paid Report Store for one-off research reports.
Five buyer types are named directly on the GenAI Search page itself: biopharma R&D/BD teams, generic & API manufacturers, CROs/CDMOs, and financial/diligence teams (VC, PE, equity research). This is a deliberately wide buyer set for a six-person-to-fifty-person team to be serving at once.
Module-based platform access. Tiering not disclosed publicly.
"Request Demo" is the dominant CTA on every feature page.
Email/password + SSO flow exists in parallel — a second, PLG-shaped funnel.
One-off report purchases, with a published refund policy — currently no visible inventory.
Market category: Life-Sciences Market & Competitive Intelligence Software — sibling category to IQVIA, Clarivate Cortellis, Evaluate (Norstella), GlobalData Pharmaceuticals, DealForma, and AlphaSense.
Doloxe has assembled a genuinely broad, well-specified product line spanning the entire drug lifecycle — discovery to price — built by a small (10–50 person), India-and-US team. The product scope rivals billion-dollar incumbents on paper; the go-to-market and trust infrastructure trails well behind category expectations.
You've built the hard part — six structured datasets plus an AI search layer most named competitors still lack. You're losing credibility on the easy part: an empty Report Store, an empty Daily News feed, a broken sign-up icon row, and inconsistent module names across the nav. In a data-trust category, these read as signal, not cosmetics.
A real wedge exists — AI-native search over pharma-native structured data, undercutting Cortellis/IQVIA price points for the under-served long tail — inside a market with enormous incumbent revenue precedent. But there is no public evidence of paying logos, retention, or even a disclosed price. The site reads pre-validation, not post-PMF.
Incumbent-class tools (Cortellis, IQVIA) are priced and built for top-20 pharma. Everyone below that line currently stitches together free registries, PDFs, and spreadsheets.
Four distinct revenue lines are already implied by the site's own structure and copy — none yet fully built out or priced.
Strong proven analog demand — but zero public proof Doloxe itself has found its segment yet.
AI-in-pharma software is estimated to grow from roughly $20B to $25B+ between 2025–2026 alone, against a global therapeutics market heading toward $2.4T by 2029 — a large and accelerating backdrop for any AI-native intelligence tool.
Four monetization surfaces, no visible pricing, no clear PLG-vs-sales-led sequencing for the buyer.
Data/SaaS economics scale well once sold; a lean offshore-plus-US team structure keeps COGS low relative to incumbents.
| Module | What it does | Primary buyer | Depth vs. category leader |
|---|---|---|---|
| GenAI Search | Cross-entity AI search over drugs, companies, trials, deals | All segments | Ambitious scope; retrieval quality unverifiable without a sandbox |
| BioPharma KSM | 12,000+ manufacturer / 18,000+ facility / 6,600+ API supply-chain map | Procurement, CDMO/CRO BD | Comparable in concept to GlobalData's manufacturing intel |
| 360 BioPharma Tracker | Pipeline + deals + executive moves + sponsor events | BD&L, market intel | Direct overlap with DealForma and Cortellis' Competitive Intelligence module |
| Clinical Trials Accelerators | Protocol benchmarking + cost/timeline optimization | Sponsors/CROs | Closer to a workflow tool than a database — genuinely differentiated if real |
| Reformulation/Repurpose | AI recommender trained on 10,000+ drugs | BD&L, portfolio strategy | No full equivalent among named competitors — strongest differentiation candidate |
| HEOR Tracker | Pricing / HTA / IRP / therapy-cost engine | Market access, payers | Overlaps Evaluate's forecasting tools, adds IRP spillover modeling |
A prospect cannot self-qualify into the right funnel, and the self-serve path dead-ends the moment an account is created. For a category where buyers expect to "kick the tires" before talking to anyone, this most likely pushes nearly all serious evaluation back onto the sales team — expensive for a 10–50 person company.
| Strengths | Broad lifecycle coverage · explicit per-segment value props · dual-geography cost base · novel repurposing + HEOR/IRP combination |
| Weaknesses | No pricing transparency · no named social proof · visible empty states (Report Store, Daily News) · copy inconsistencies undercut a data-accuracy brand |
| Opportunities | Long tail of CROs/biotechs/generics priced out of Cortellis/IQVIA · AI-native conversational search where most incumbents remain structured-only · HEOR+Repurposing bundle is genuinely uncrowded |
| Threats | IQVIA, Clarivate, Norstella/Evaluate, GlobalData are adding GenAI layers fast with decades of curated trust · AlphaSense is claiming "AI search + life sciences" from the financial-services side |
| Tier | Title | Industry | Company size | Core trigger |
|---|---|---|---|---|
| Primary | Competitive Intelligence / BD&L Manager | Mid-size biotech & specialty pharma | 50–2,000 employees | Losing pipeline visibility before a board update or partnering conversation |
| Secondary | BD & Regulatory Affairs Lead | Generic drug & API manufacturer | 100–5,000 | LoE / ANDA prioritization cycle, capacity bidding |
| Enterprise | Market Access/HEOR Director, or VC-PE Diligence Principal | Top-20 pharma or life-sciences fund | 5,000+ / fund AUM $100M+ | Payer negotiation prep, or live deal diligence under time pressure |
Manually stitching ClinicalTrials.gov, press releases, and paid PDFs into one competitor view. No AI search layer in her current spreadsheet-plus-PDF stack.
A single AI-searchable view of pipeline, deals, and executive moves, exportable for Monday's leadership deck.
Board prep cycle; a competitor surprise she missed last quarter.
"Is this data verified the way Cortellis's PhD curators verify theirs?" No published price makes her unsure if this is even built for a team her size. Champion-led trial request → 1–2 internal sign-offs → procurement/security review.
Manually tracking patent expiry/LoE dates across hundreds of molecules to time ANDA filings; incumbent tools are priced out of reach.
An LoE/patent-expiry watchlist plus capacity-bid intelligence from BioPharma KSM.
New fiscal-year portfolio planning; an upcoming LoE wave in his therapeutic area.
"How is a 12,000-manufacturer dataset kept current?" Cost-sensitive; BD head approves directly; often wants a paid pilot before an annual commitment.
HTA dossier prep across 50+ reference markets is slow and manual; deal diligence needs same-day turnaround.
HEOR/IRP scenario modeling tied to live pipeline data; a one-click company/asset diligence brief.
Upcoming HTA submission deadline; a live partnering or financing decision.
Procurement requires SOC2/security documentation Doloxe doesn't publish; needs data-lineage proof. Multi-stakeholder, 3–6 month cycle, requires a champion plus an executive sponsor.
Positioning is the engagement team's qualitative read based on each platform's publicly described capabilities — not a vendor-disclosed benchmark.
| Capability | Doloxe | IQVIA | Cortellis | Evaluate | GlobalData | DealForma | AlphaSense |
|---|---|---|---|---|---|---|---|
| Conversational / GenAI search | ✓* | ◐ | — | — | — | — | ✓ |
| End-to-end pipeline tracking | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ | — |
| Deal / M&A tracking | ✓ | — | ◐ | ◐ | ✓ | ✓ | ◐ |
| Manufacturing / supply-chain mapping | ✓ | ◐ | — | — | ◐ | — | — |
| HEOR / pricing / IRP modeling | ✓ | ◐ | ◐ | ◐ | ◐ | — | — |
| AI repurposing recommender | ✓ | — | — | — | — | — | — |
| À la carte module pricing | ? | — | ✓ | ◐ | ◐ | ◐ | — |
| Publicly referenced top-20-pharma logos | — | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
* Claimed on-site; not independently testable without product access. ✓ strong / ◐ partial / — not evidenced.
No named competitor combines true conversational search with deep pharma-specific structured data — incumbents have one or the other, not both.
Nobody else bundles pricing/HTA/IRP modeling with an AI repurposing recommender. This combination is structurally rare.
CROs, API makers, and sub-$500M biotechs are underserved by tools built and priced for top-20 pharma — a clear price-segment whitespace.
Transparent, tiered, module-based pricing — nobody in the comparison set offers this clearly today.
Market the repurposing/HEOR combination first, not a "we do everything" pitch that invites direct comparison to IQVIA.
Make GenAI search demoable with no login. Incumbents move slowly here — Doloxe can move fast.
The headline ("Drug Research, Clinical & Regulatory Data") is accurate but generic — it doesn't differentiate from any of the six named competitors. The six module cards beneath it do more positioning work than the hero itself.
Leads with a stock-style AI-brain graphic and a six-module grid rather than a single "this is for you if…" statement — a first-time visitor must self-segment immediately, with no guidance.
"Sign Up" and "Login" sit in the nav with no primary hero CTA button at all. The strongest CTA ("Request Demo") only appears once a visitor has already drilled into a feature page.
Three anonymized testimonials, one unsourced stat (72%), two office addresses — no logos, no security badges, no press mentions, no usage numbers.
A flat, sensible 8-item top nav (Home / Key Features dropdown of 6 / Report Store / Daily News / About / Contact / Login / Sign Up) — easy to scan, no deep nesting.
Module names drift between the nav label, page H1, and page title for the same feature — e.g. "Repurpose / ReFormulation" in the nav vs. "Reformulation & Repurpose" as the H1 vs. "Reformulation & Repurpose Platform" in the title tag. Small, but compounding for a data-precision brand.
Consistent card-and-icon layout per feature page; long-form copy is genuinely well organized into numbered sub-sections and named buyer-benefit blocks.
Not independently testable via static review, but dense multi-column footers (contact details + two addresses + legal links) repeat verbatim on every page — a common source of mobile scroll fatigue, alongside the homepage's six-module grid and large hero illustration.
Organic or referral visit to homepage or a feature page
Sign Up or Request Demo — no guidance on which
Contact form only — no calendar booking; no onboarding email after sign-up
Sales response promised "within 24 hours" per the Contact page
Report Store — a second conversion path — currently converts nobody (no inventory)
Removing the contact-form round-trip and giving the self-serve path a real next step are the two highest-leverage, lowest-cost fixes on this map.
Fix broken SSO icons; fix empty/typo'd filter states; align module naming; add one clear hero CTA.
Est. uplift: 10–20% reduction in first-touch bounce (directional)
Publish starting pricing or a "quote in 24h" guided form; add 3–5 quantified case studies; add a self-serve product tour.
Est. uplift: 15–30% lift in demo-request conversion (directional)
Ship a no-login GenAI search demo widget embedded in the homepage hero; add a calendar-booking widget to remove the contact-form round trip.
Est. uplift: largest single lever — could plausibly raise demo-to-opportunity conversion meaningfully in a see-it-to-believe-it category (directional, not guaranteed)
| Keyword | Intent | Competition | Opportunity |
|---|---|---|---|
| clinical trial benchmarking software | Commercial | Medium | High |
| biopharma competitive intelligence platform | Commercial | High | Medium |
| drug repurposing AI | Info/Commercial | Low | High |
| API manufacturer database | Commercial | Low–Med | High |
| HTA dossier software | Commercial | Low | High |
| drug patent expiry tracker | Commercial | Medium | High |
| Cortellis alternative | Comparison | Low | High |
| IQVIA alternative for biotech | Comparison | Low | High |
| international reference pricing tool | Commercial | Low | High |
| CDMO capacity database | Commercial | Low | Medium |
Technical cleanup: fix empty/thin pages, sitemap, per-page meta descriptions. Ship "Doloxe vs. Cortellis" / "vs. GlobalData" comparison pages to capture cheap switcher intent.
Build a keyword-cluster content hub around LoE/patent-expiry and drug repurposing — the least competitive, most differentiated topics identified above.
Backlink push via contributed data/stats to pharma trade press; Daily News becomes a real, frequently-updated content engine — also fixing the Phase 5/6 empty-state problem.
| Channel | Strategy | Action | Budget | KPI |
|---|---|---|---|---|
| SEO | Comparison + LoE/repurposing content hub | 2 posts/wk | Low | Organic demo requests |
| Founder-led posts on pipeline data & repurposing finds | 3–4 posts/wk + 10 outbound DMs/day | Low | Inbound connection → demo rate | |
| X / Twitter | Real-time pharma news commentary using Daily News as raw material | Daily | Low | Followers → site clicks |
| YouTube | 5-min screen-recorded "found this signal" demos | 2/month | Low–Med | Demo requests attributed |
| Nurture sequence for self-serve signups who haven't activated | Automated, 5-email sequence | Low | Trial → paid conversion | |
| Communities | BIO/JPM Healthcare groups, r/biotech | Weekly participation | Low | Referral traffic |
| Partnerships | Co-marketing with smaller CROs/CDMOs | 1–2 deals/quarter | Medium | Partner-sourced pipeline |
| Product Hunt | Launch GenAI Search as a standalone "AI for biotech BD" tool | 1 launch | Low | Launch-day signups |
| Referral | Free month per qualified referral for self-serve users | Ongoing | Low | Referral-sourced signups |
Fix the website-credibility issues from Phases 5–6; publish pricing or a clear "request pricing" path; ship the no-login GenAI demo widget.
Launch comparison-page SEO content; start LinkedIn founder-led content + outbound; run a Product Hunt launch for GenAI Search.
One inbound content engine generating qualified demo requests monthly; 2+ referenceable (even anonymized-but-quantified) case studies; a self-serve tier with real activation data.
LinkedIn Sales Navigator search by title (BD&L, Competitive Intelligence, Regulatory Affairs) at mid-size biotech, generics, and CDMO companies, plus outbound to VC/PE life-sciences associates.
Lead → 15-min discovery call → live demo on the prospect's own pipeline data → pilot/trial → contract.
4-touch LinkedIn sequence (connect → value-add comment → DM with a specific repurposing/LoE insight about their own pipeline → demo ask) run in parallel with a 3-email cold sequence.
At 10–50 employees, HubSpot CRM or Pipedrive over Salesforce — Salesforce earns its cost only once the enterprise/top-20-pharma motion has real volume.
"Saw [Company]'s recent [therapeutic area] readout — ran it through our repurposing model and found [X] under-the-radar reformulation angles. Worth 10 minutes to compare notes?"
Subject: [Company]'s pipeline — found something
Hi [Name] — noticed [Company] is approaching [milestone] on [asset]. We ran it through Doloxe's repurposing & LoE models and found a couple of angles your team may not be tracking yet.
Worth a 15-minute call this week?
| Tier | Who it's for | What's included | Positioning |
|---|---|---|---|
| Starter / Self-serve | Individual analysts, small biotech BD | GenAI Search + limited monthly queries | Low-cost entry, card-based self-serve |
| Professional | Mid-size biotech, CRO/CDMO BD teams | 2–3 modules of choice + seats | Module-based annual contract |
| Enterprise | Top-20 pharma, large CDMOs, VC/PE funds | Full suite + API + dedicated "Ask Analyst" | Custom, sales-led annual contract |
A time- or query-limited GenAI Search trial with no credit card — it's the cheapest module to demo and the single most persuasive thing the product can show.
Upsell: single-module → multi-module bundle. Cross-sell: platform subscribers → Report Store one-off reports. Expansion: per-seat growth + API/data-licensing add-on.
🟡 Every figure below is illustrative, modeled from comparable vertical data-SaaS benchmarks — not Doloxe's actual books.
| Segment | Modeled ACV | Modeled CAC | Modeled gross margin | Modeled LTV:CAC |
|---|---|---|---|---|
| Self-serve / Starter | $1,500–4,000/yr | $300–800 | 75–85% | 4–6x |
| Professional | $15,000–40,000/yr | $3,000–8,000 | 75–85% | 5–8x |
| Enterprise | $75,000–250,000+/yr | $15,000–40,000 | 70–80% | 6–10x |
| Scenario | Logos by month 12 | ARR by month 12 | Mix |
|---|---|---|---|
| Conservative | 8–15 | $150K–$300K | Mostly Starter/Professional |
| Expected | 20–35 | $500K–$900K | First 1–2 Enterprise logos |
| Aggressive | 40–60 | $1.2M–$2.0M | 3–5 Enterprise logos; Report Store ~10–15% of revenue |
Treat these as planning anchors to replace with real pipeline data the moment a pricing page and first contracts exist.
| Feature | User value | Dev complexity | Revenue impact | Edge | Priority |
|---|---|---|---|---|---|
| No-login conversational demo widget | Self-qualify in 30 seconds | Low | High | Incumbents can't move this fast | P0 |
| Auto-populated Daily News via the existing engine | Fixes the empty-state credibility gap | Medium | Medium | Turns a liability into a feature | P0 |
| Predictive "Likelihood of Approval"-style scoring | Differentiates the pipeline tracker from a static list | High | High | Matches GlobalData's known flagship feature | P1 |
| Internal-document RAG upload | Smaller biotechs analyze their own diligence docs alongside Doloxe data | High | Med–High | None of the pharma-native competitors offer this | P2 |
| Agentic BD&L "deal-finder" | Proactively flags repurposing + licensing matches | High | High | Turns a passive database into a daily-use tool | P2 |
| Item | Reach | Impact | Confidence | Effort | RICE | Window |
|---|---|---|---|---|---|---|
| UX/CRO quick-win fixes | High | High | High | Low | Very High | Month 1 |
| Publish pricing | High | High | Med | Low | High | Month 1 |
| No-login GenAI demo widget | High | High | Med | Med | High | Months 1–2 |
| Comparison-page SEO content | Med | Med | High | Low | High | Months 1–3 |
| Security/compliance page + SOC2 roadmap commitment | Med | High | Med | Low | High | Months 2–3 |
| Daily News auto-population | Med | Med | High | Med | Med–High | Months 2–3 |
| Case studies / social-proof program | High | High | Med | Med | High | Months 2–4 |
| Module-based pricing page + self-serve checkout | High | High | Med | Med | High | Months 3–4 |
| Predictive scoring model (P1 AI feature) | Med | High | Med | High | Medium | Months 4–8 |
| Internal-document RAG upload | Med | Med | Low | High | Low–Med | Months 8–12 |
Framed as a structured planning exercise for the founder, not real investment advice or a solicitation.
Real product depth, a genuine wedge (AI-native + pharma-native, none of the named incumbents occupy both), a large proven category, and a lean cost base.
No disclosed pricing, customers, or retention; a small team facing well-capitalized incumbents; website execution gaps that read as broader execution risk in diligence; unclear PLG-vs-enterprise identity.
3–5 referenceable paying logos, net revenue retention, CAC payback period, module-level usage data, and a repeatable ICP definition (not "all of biopharma").
① Ship and prove the no-login demo. ② Land and case-study 3 reference logos across the three ICP tiers. ③ Publish a coherent pricing architecture. ④ Lead with the repurposing+HEOR wedge for two quarters before broadening the pitch again.
| # | Action | Impact | Effort | Cost | Time |
|---|---|---|---|---|---|
| 1 | Fix broken SSO icon row on sign-up ("GMOoe") | High | Low | $ | <1 wk |
| 2 | Fix "Biacrins" and other filter-label typos on Daily News | High | Low | $ | <1 wk |
| 3 | Replace empty Report Store state with real inventory or an honest "launching soon" waitlist | High | Med | $ | 1–2 wk |
| 4 | Replace empty Daily News default with seeded content or a clear explanation | High | Med | $ | 1–2 wk |
| 5 | Align module naming across nav, H1, and title tags | Med | Low | $ | <1 wk |
| 6 | Add one primary CTA button to the homepage hero | High | Low | $ | <1 wk |
| 7 | Write a unique meta description per page | Med | Low | $ | 1 wk |
| 8 | Add an HTML sitemap / footer links to all module pages | Med | Low | $ | 1 wk |
| 9 | Add a "what happens after I sign up?" line to the sign-up page | Med | Low | $ | <1 wk |
| 10 | Add a calendar-booking link to Contact instead of form-only | High | Low | $ | <1 wk |
| 11 | Add alt text / fix broken image elements site-wide | Med | Low | $ | 1 wk |
| 12 | Publish a "starting at $X" or "request pricing in 24h" anchor | High | Low | $ | 1 wk |
| 13 | Populate and keep the LinkedIn company page active | Low | Low | $ | <1 wk |
| 14 | Standardize "GenAI" capitalization across all pages | Low | Low | $ | <1 wk |
| 15 | Add breadcrumbs on feature pages for IA clarity | Low | Low | $ | 1 wk |
| 16 | Add a short "Doloxe vs. [incumbent]" snippet to each feature page | Med | Med | $ | 2 wk |
| 17 | Source and cite the homepage's 72% efficiency stat | High | Low | $ | <1 wk |
| 18 | Add a visible response-time/SLA note near "Ask Analyst" | Med | Low | $ | <1 wk |
| 19 | Add basic Organization structured data for richer search snippets | Med | Low | $ | 1 wk |
| 20 | Run a full sitewide proofread pass (4+ typos already found) | High | Low | $ | 1 wk |
| # | Action | Impact | Effort | Cost | Time |
|---|---|---|---|---|---|
| 1 | No-login interactive GenAI search demo on homepage | High | Med | $$ | 4–6 wk |
| 2 | Build 3–5 anonymized but quantified case studies | High | Med | $ | 4 wk |
| 3 | Comparison-page SEO content ("vs. Cortellis", "vs. IQVIA") | High | Low | $ | Ongoing |
| 4 | LinkedIn founder-led content + outbound program | High | Low | $ | Ongoing |
| 5 | Product Hunt launch for GenAI Search as a standalone tool | Med | Low | $ | 2 wk prep |
| 6 | Partner co-marketing with mid-size CROs/CDMOs | Med | Med | $$ | Quarterly |
| 7 | LoE/patent-expiry content hub | High | Med | $ | 6–8 wk |
| 8 | Repurposing-signal content series for BD&L | High | Med | $ | 6–8 wk |
| 9 | Sponsor/attend one mid-tier (non-JPM-scale) conference | Med | Med | $$ | Quarterly |
| 10 | Referral program for self-serve users | Med | Low | $ | 4 wk |
| 11 | YouTube "insight of the week" screen-recorded series | Med | Med | $ | Ongoing |
| 12 | API/data-licensing pitch for analytics-heavy customers | Med | High | $$ | 8–12 wk |
| 13 | Convert anonymized testimonials to named logos (incentivized) | High | Low | $ | Ongoing |
| 14 | Target India/APAC biotech & CRO market via existing HQ presence | Med | Med | $ | Quarterly |
| 15 | "Switch from spreadsheets" onboarding funnel for SMB biotech | Med | Med | $ | 8 wk |
| 16 | Webinar series with a guest regulatory/KOL expert | Med | Med | $$ | Quarterly |
| 17 | Press push around the Reformulation/Repurpose AI engine | Med | Low | $ | 4 wk |
| 18 | Academic/VC partnerships for due-diligence use cases | Med | Med | $ | Quarterly |
| 19 | Build integrations (Excel/Slack export, Salesforce) | High | High | $$ | 3–6 mo |
| 20 | IRP thought-leadership content tied to live US/EU policy debates | Med | Low | $ | Ongoing |
| # | Action | Impact | Effort | Cost | Time |
|---|---|---|---|---|---|
| 1 | Publish module-based self-serve pricing with online checkout | High | Med | $$ | 6–8 wk |
| 2 | Activate the Report Store with even 10–15 real reports | High | Med | $$ | 6–10 wk |
| 3 | Launch "Ask Analyst" as a paid advisory add-on tier | High | Low | $ | 4 wk |
| 4 | API/data-licensing revenue line for BI-heavy customers | High | High | $$ | 3–6 mo |
| 5 | Annual-prepay discount to improve cash flow & reduce churn risk | Med | Low | $ | 2 wk |
| 6 | Per-seat expansion pricing once initial logos land | Med | Low | $ | Ongoing |
| 7 | Bundle HEOR + Repurposing as a premium "Lifecycle Strategy" package | High | Med | $ | 6 wk |
| 8 | Enterprise package tailored to VC/PE diligence teams | High | Med | $$ | 8 wk |
| 9 | Conference-timed pop-up trials (JPM Healthcare / BIO) | Med | Low | $ | Quarterly |
| 10 | Paid pilot program (60–90 days, fee-bearing) for Enterprise | Med | Low | $ | 4 wk |
| 11 | Co-branded reports with press/analysts for lead-gen + syndication | Med | Med | $ | Quarterly |
| 12 | Usage-based overage pricing for GenAI Search query volume | Med | Med | $ | 8 wk |
| 13 | White-label data feed for boutique CI consultancies | Med | High | $$ | 3–6 mo |
| 14 | Training/certification add-on for analyst teams | Low | Med | $ | Quarterly |
| 15 | Extend the existing USD selector to INR/EUR for regional sales | Med | Med | $ | 4 wk |
| 16 | Renewal-time upsell playbook tied to usage data | Med | Low | $ | Post-data |
| 17 | Sponsored insights slot within Daily News once live | Med | Med | $ | Post-launch |
| 18 | Volume licensing deals with CDMO/CRO trade associations | Med | High | $$ | 6 mo+ |
| 19 | Equity-research package bundling forecasting + repurposing data | High | High | $$ | 6 mo+ |
| 20 | Refer-a-customer revenue share for boutique pharma consultants | Med | Med | $ | Quarterly |
Reading the pattern: the underlying asset (Product, Growth Potential) scores well above the go-to-market machinery built around it (Monetization, Marketing, Sales). That gap is the 90-day opportunity.
| 1. Biggest opportunity | Owning the "AI-native + pharma-native" white space no named competitor occupies, aimed at the long tail incumbents price out. |
| 2. Biggest weakness | Total pricing and proof opacity — nobody can self-qualify, and the credibility-critical surfaces (Report Store, Daily News) are visibly empty. |
| 3. Fix immediately | The empty states, the broken SSO row, and the naming inconsistencies — all low-cost, high-credibility-damage items. |
| 4. Build next | The no-login GenAI search demo widget — the cheapest, fastest, most persuasive thing the product can ship, since the engine already exists. |
| 5. Fastest revenue | Activating the Report Store (the commerce/legal scaffolding already exists) and launching "Ask Analyst" as a paid advisory tier. |
| 6. What makes this $10M+ | Picking the repurposing + HEOR wedge, proving it with 5+ paying reference logos, and using that proof to fund a real content+outbound GTM motion. |
| 7. 90-day founder focus | Credibility fixes (wks 1–2) → demo widget + pricing page (wks 3–6) → first 3 reference logos via the repurposing wedge (wks 6–12). |
Prepared as a structured strategic diagnostic, not a guarantee of outcomes — every modeled number is a planning assumption to be replaced with real data as it arrives.